Bukwang Pharm Q3 2026 YTD Operating Profit Falls 22% Year Over Year to KRW 4.7 Billion

Bitget2026/10/23 01:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Bukwang Pharm’s consolidated operating profit fell 22% year over year to KRW 4.7 billion in the first nine months of 2026.
Revenue rose 18% year over year to KRW 162.7 billion, supported by strategic-product prescription growth and increased subsidiary contributions.
The operating profit decline stemmed mainly from research and development spending, which climbed 30% year over year to KRW 16.9 billion.
Contera Pharma secured US clearance for its CP-012 Phase 2 Parkinson’s trial and is preparing to start the study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bukwang Pharm. Co. Ltd. published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Bukwang Pharm Q3 2026 YTD Operating Profit Falls 22% Year Over Year to KRW 4.7 Billion

You may also like

Crypto prices